Antibodies vs small molecules

Welcome to this lecture on antibodies versus small molecules, providing an overview of the key differences between antibody and small molecule therapeutics, focusing on their mechanisms, pharmacokinetic properties, and clinical applications. We will discuss how factors like drug size, structure, and root of administration influence their use, benefits and limitations. Additionally, we will examine how clinicians select between these agents based on target location, specificity, dosing requirements, and practicality. Finally, we'll highlight emerging innovations that are redefining the boundaries and applications of these therapies in modern medicine. We'll explore two major classes of therapeutic agents, antibodies and small molecules, emphasizing their advantages, limitations, and clinical scenarios where one may be favored. As medicine advances, both are increasingly leveraged from traditional small molecules like aspirin to monoclonal antibodies for cancer or auto immune diseases. Understanding their differences is crucial for rational drug design. This lecture will examine how size, structure, and mechanism affect their suitability and clinical use. A defining difference between antibodies and small molecules is their ability to access targets. Monoclonal antibodies are large proteins, about 150 kilodaltons, administered perenterally, circulating in vascular and interstitial spaces. This size restricts them to extracellular environments, making them ideal for targeting circulating proteins,